Publication: Potassium-competitive acid blockers and gastroesophageal reflux disease
0
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
10079327
Rights Holder(s)
Scopus
Bibliographic Citation
Environmental Technology (United Kingdom). Vol , No. (2022), p.-
Suggested Citation
Leowattana W., Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. Environmental Technology (United Kingdom). Vol , No. (2022), p.-. doi:10.3748/wjg.v28.i28.3608 Retrieved from: https://hdl.handle.net/20.500.14740/9836
Author(s)
Abstract
Proton pump inhibitors (PPIs), the most commonly used antisecretory medications in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy. However, PPI medications still leave some therapeutic demands of GERD unmet. Furthermore, up to 40%-55% of daily PPI users have chronic symptoms, due to PPI refractoriness. Potassium-competitive acid blockers (P-CABs) transcend many of the problems and limits of PPIs, delivering quick, powerful, and extended acid suppression and allowing for treatment of numerous unmet needs. Recently, it has become clear that compromised mucosal integrity plays a role in the etiology of GERD. As a result, esophageal mucosal protection has emerged as a novel and potential treatment approach. An increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs (to regular treatment), they provide a considerable extra benefit, particularly in alleviating symptoms that do not respond to PPI therapy. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.